A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.

Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA
Clin Cancer Res. 2013 19 (1): 258-67

PMID: 23082002 · DOI:10.1158/1078-0432.CCR-12-1800

MeSH Terms (23)

Adult Aged Aged, 80 and over Anilides Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Bevacizumab Camptothecin Colorectal Neoplasms Female Fluorouracil Humans Leucovorin Male Maximum Tolerated Dose Middle Aged Neoplasm Metastasis Organoplatinum Compounds Proto-Oncogene Proteins Proto-Oncogene Proteins p21(ras) Pyridines ras Proteins Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: